Azitra, a clinical-stage biopharmaceutical company, announced that COO Travis Whitfill will present virtually at the H.C. Wainwright 28th Annual Global Investment Conference in September 2026. He will share updates on Azitra's pipeline, including initial data from the ATR-COSF program targeting cosmetic applications like fine lines and wrinkles, and ongoing Phase 1/2 trials for ATR-04 treating EGFR inhibitor-associated rash. The presentation highlights Azitra's strategy to expand its microbial genetic engineering platform beyond traditional therapeutics into cosmeceuticals. The company also plans one-on-one investor meetings to discuss recent achievements and future milestones.
Opus Genetics, a clinical-stage biotech focused on inherited retinal diseases, received a Buy rating and $8 price target from analyst Matthew Caufield in August 2026. The company plans to release topline Phase 1/2 data for its gene therapy OPGx-BEST1...
General Electric (GE) announced it will acquire Consolidated Precision Products (CPP) for $11.75 billion to enhance its aerospace casting production. This strategic move aims to strengthen GE's manufacturing capabilities and accelerate engine technol...
United Natural Foods, Inc. (UNFI) reported a Q4 adjusted EPS of $0.69, surpassing analyst expectations of $0.61, signaling strong profitability. However, revenue slightly missed estimates at $7.64 billion, down 0.7% from the previous year. Despite th...
Ionis Pharmaceuticals faced a setback when its experimental heart drug pelacarsen failed a Phase 3 trial to reduce cardiovascular events, causing an 8.6% stock drop. However, an analyst from Canaccord Genuity maintained a bullish $85 price target, im...
Casey's General Stores will release its Q3 2026 earnings on September 8 after market close, with analysts expecting an EPS of $6.78 and revenue of $5.56 billion. The company has a strong history of exceeding earnings estimates, with an average surpri...
